Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors
Background: Cancer treatments have gradually evolved into targeted molecular therapies characterized by a unique mechanism of action instead of non-specific cytotoxic chemotherapies. However, they have unique safety concerns. For instance, endocrinopathies, which are defined as unfavorable metabolic...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Medical Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3271/10/4/65 |
| _version_ | 1797456385975255040 |
|---|---|
| author | Atika AlHarbi Majed Alshamrani Mansoor Khan Abdelmajid Alnatsheh Mohammed Aseeri |
| author_facet | Atika AlHarbi Majed Alshamrani Mansoor Khan Abdelmajid Alnatsheh Mohammed Aseeri |
| author_sort | Atika AlHarbi |
| collection | DOAJ |
| description | Background: Cancer treatments have gradually evolved into targeted molecular therapies characterized by a unique mechanism of action instead of non-specific cytotoxic chemotherapies. However, they have unique safety concerns. For instance, endocrinopathies, which are defined as unfavorable metabolic alterations including thyroid disorders, hyperglycemia, dyslipidemia, and adrenal insufficiency necessitate additional monitoring. The aim of this study was to assess the prevalence of monitoring errors and develop strategies for monitoring cancer patients who receive targeted therapies. Method: A retrospective chart review was used to assess the prevalence of monitoring errors of endocrinopathies among cancer patients who received targeted therapies over one year. All of the adult cancer patients diagnosed with a solid tumor who received targeted therapies were included. The primary outcome was to determine the prevalence of monitoring errors of endocrinopathies. The secondary outcomes were to assess the incidences of endocrinopathies and referral practice to endocrinology services. Results: A total of 128 adult patients with solid tumors were involved. The primary outcome revealed a total of 148 monitoring errors of endocrinopathies. Monitoring errors of the lipid profile and thyroid functions were the most common error types in 94% and 92.6% of the patients treated with novel targeted therapies, respectively. Subsequently, 57% of the monitoring errors in the blood glucose measures were identified. Targeted therapies caused 63 events of endocrinopathies, hyperglycemia in 32% of the patients, thyroid disorders in 15.6% of them and dyslipidemia in 1.5% of the patients. Conclusion: Our study showed a high prevalence of monitoring errors among the cancer patients who received targeted therapies which led to endocrinopathies. It emphasizes the importance of adhering to monitoring strategies and following up on the appropriate referral process. |
| first_indexed | 2024-03-09T16:06:53Z |
| format | Article |
| id | doaj.art-57d42a4568a74bf891492a6ffe63061e |
| institution | Directory Open Access Journal |
| issn | 2076-3271 |
| language | English |
| last_indexed | 2024-03-09T16:06:53Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medical Sciences |
| spelling | doaj.art-57d42a4568a74bf891492a6ffe63061e2023-11-24T16:34:35ZengMDPI AGMedical Sciences2076-32712022-11-011046510.3390/medsci10040065Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid TumorsAtika AlHarbi0Majed Alshamrani1Mansoor Khan2Abdelmajid Alnatsheh3Mohammed Aseeri4Department of Pharmaceutical Care Services, Princess Noorah Oncology Center (PNOC), King Abdulaziz Medical City (KAMC), Ministry of National Guard Health Affairs (MNGHA), P.O. Box 9515, Jeddah 21423, Saudi ArabiaDepartment of Pharmaceutical Care Services, Princess Noorah Oncology Center (PNOC), King Abdulaziz Medical City (KAMC), Ministry of National Guard Health Affairs (MNGHA), P.O. Box 9515, Jeddah 21423, Saudi ArabiaDepartment of Pharmaceutical Care Services, Princess Noorah Oncology Center (PNOC), King Abdulaziz Medical City (KAMC), Ministry of National Guard Health Affairs (MNGHA), P.O. Box 9515, Jeddah 21423, Saudi ArabiaDepartment of Pharmaceutical Care Services, Princess Noorah Oncology Center (PNOC), King Abdulaziz Medical City (KAMC), Ministry of National Guard Health Affairs (MNGHA), P.O. Box 9515, Jeddah 21423, Saudi ArabiaDepartment of Pharmaceutical Care Services, Princess Noorah Oncology Center (PNOC), King Abdulaziz Medical City (KAMC), Ministry of National Guard Health Affairs (MNGHA), P.O. Box 9515, Jeddah 21423, Saudi ArabiaBackground: Cancer treatments have gradually evolved into targeted molecular therapies characterized by a unique mechanism of action instead of non-specific cytotoxic chemotherapies. However, they have unique safety concerns. For instance, endocrinopathies, which are defined as unfavorable metabolic alterations including thyroid disorders, hyperglycemia, dyslipidemia, and adrenal insufficiency necessitate additional monitoring. The aim of this study was to assess the prevalence of monitoring errors and develop strategies for monitoring cancer patients who receive targeted therapies. Method: A retrospective chart review was used to assess the prevalence of monitoring errors of endocrinopathies among cancer patients who received targeted therapies over one year. All of the adult cancer patients diagnosed with a solid tumor who received targeted therapies were included. The primary outcome was to determine the prevalence of monitoring errors of endocrinopathies. The secondary outcomes were to assess the incidences of endocrinopathies and referral practice to endocrinology services. Results: A total of 128 adult patients with solid tumors were involved. The primary outcome revealed a total of 148 monitoring errors of endocrinopathies. Monitoring errors of the lipid profile and thyroid functions were the most common error types in 94% and 92.6% of the patients treated with novel targeted therapies, respectively. Subsequently, 57% of the monitoring errors in the blood glucose measures were identified. Targeted therapies caused 63 events of endocrinopathies, hyperglycemia in 32% of the patients, thyroid disorders in 15.6% of them and dyslipidemia in 1.5% of the patients. Conclusion: Our study showed a high prevalence of monitoring errors among the cancer patients who received targeted therapies which led to endocrinopathies. It emphasizes the importance of adhering to monitoring strategies and following up on the appropriate referral process.https://www.mdpi.com/2076-3271/10/4/65targeted therapymonitoring errorsendocrinopathiesthyroid disordershyperglycemiadyslipidemia |
| spellingShingle | Atika AlHarbi Majed Alshamrani Mansoor Khan Abdelmajid Alnatsheh Mohammed Aseeri Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors Medical Sciences targeted therapy monitoring errors endocrinopathies thyroid disorders hyperglycemia dyslipidemia |
| title | Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors |
| title_full | Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors |
| title_fullStr | Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors |
| title_full_unstemmed | Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors |
| title_short | Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors |
| title_sort | real world experience of monitoring practice of endocrinopathies associated with the use of novel targeted therapies among patients with solid tumors |
| topic | targeted therapy monitoring errors endocrinopathies thyroid disorders hyperglycemia dyslipidemia |
| url | https://www.mdpi.com/2076-3271/10/4/65 |
| work_keys_str_mv | AT atikaalharbi realworldexperienceofmonitoringpracticeofendocrinopathiesassociatedwiththeuseofnoveltargetedtherapiesamongpatientswithsolidtumors AT majedalshamrani realworldexperienceofmonitoringpracticeofendocrinopathiesassociatedwiththeuseofnoveltargetedtherapiesamongpatientswithsolidtumors AT mansoorkhan realworldexperienceofmonitoringpracticeofendocrinopathiesassociatedwiththeuseofnoveltargetedtherapiesamongpatientswithsolidtumors AT abdelmajidalnatsheh realworldexperienceofmonitoringpracticeofendocrinopathiesassociatedwiththeuseofnoveltargetedtherapiesamongpatientswithsolidtumors AT mohammedaseeri realworldexperienceofmonitoringpracticeofendocrinopathiesassociatedwiththeuseofnoveltargetedtherapiesamongpatientswithsolidtumors |